-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Videos|April 23, 2019

ISPOR 2019: On Location Interviews, Day 3

Interviews with Yousuf Zafar, MD, of Duke Cancer Institute, and Lou Garrison, PhD, of University of Washington, from day 3 of the ISPOR 2019 annual meeting in New Orleans, Louisiana. You can now watch day 1 and day 2.

You can now watch day 1 and day 2.

Today, we are on site for day 3 of ISPOR 2019 annual meeting in New Orleans, Louisiana!

We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Yousuf Zafar, MD, associate professor of medicine and population health sciences at Duke University School of Medicine and a medical oncologist at Duke Cancer Institute, and Lou Garrison, PhD, a professor emeritus in the Department of Pharmacy at University of Washington.

Welcome to AJMC® on location, I’m Jaime Rosenberg!

The third day of the conference covered several hot topics that require innovative ways of thinking about healthcare. First, there was a session on biosimilars and addressing the legal, regulatory, and coverage challenges. There was also a session that explored how meaningful models can be constructed for rare conditions. Finally, there was a session on the affordability of prescription drugs with high price tags continue to enter the market.

Read coverage and watch additional interviews from the meeting at AJMC.com.

That’s all from the ISPOR 2019 annual meeting. Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.


Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.